As the upcoming elections in the United States quickly approach, one of the key issues in the spotlight is the debate surrounding the rescheduling of medical marijuana. Currently, medical marijuana is federally classified as a Schedule I substance, meaning it has no medicinal value and leaving it extremely difficult to research the good or the bad behind the plant. While some research does exist on the safety and efficacy of marijuana in the treatment of a wide range of symptoms and conditions, there is still much left to be desired. Recent reports suggest the DEA could be coming to a close on their decision to reschedule marijuana, and the decision to reclassify the drug would have a significant impact on researching its vast potential as a powerful medication.
The Scientific American does an excellent job of explaining just how marijuana's reclassification would benefit marijuana research by showcasing different scientists and describing the struggles they face under marijuana's current scheduling. Read this feature for a magnified look at the current state of medical marijuana studies and for insight on how reclassifying marijuana would revolutionize its research. This information has been approved by out Chief Medical Officer.